135 related articles for article (PubMed ID: 1697039)
1. Beta 2-microglobulin restriction of antigen presentation.
Pérarnau B; Siegrist CA; Gillet A; Vincent C; Kimura S; Lemonnier FA
Nature; 1990 Aug; 346(6286):751-4. PubMed ID: 1697039
[TBL] [Abstract][Full Text] [Related]
2. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
Uger RA; Barber BH
J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
[TBL] [Abstract][Full Text] [Related]
3. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
Zügel U; Schoel B; Kaufmann SH
J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
[TBL] [Abstract][Full Text] [Related]
4. The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m.
Pedersen LO; Stryhn A; Holter TL; Etzerodt M; Gerwien J; Nissen MH; Thøgersen HC; Buus S
Eur J Immunol; 1995 Jun; 25(6):1609-16. PubMed ID: 7614989
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.
Jefferies WA; Kolaitis G; Gabathuler R
J Immunol; 1993 Sep; 151(6):2974-85. PubMed ID: 8397249
[TBL] [Abstract][Full Text] [Related]
6. Restricted recognition of beta 2-microglobulin by cytotoxic T lymphocytes.
Rammensee HG; Robinson PJ; Crisanti A; Bevan MJ
Nature; 1986 Feb 6-12; 319(6053):502-4. PubMed ID: 3511388
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice.
Barra C; Pérarnau B; Gerlinger P; Lemeur M; Gillet A; Gibier P; Lemonnier FA
J Immunol; 1989 Nov; 143(10):3117-24. PubMed ID: 2478616
[TBL] [Abstract][Full Text] [Related]
8. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells.
Jhaver KG; Rao TD; Frey AB; Vukmanović S
J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863
[TBL] [Abstract][Full Text] [Related]
9. Antigen presentation and the association of class-I molecules.
Elliott TJ; Cerundolo V; Ohlen C; Ljunggren HG; Karre K; Townsend A
Acta Biol Hung; 1991; 42(1-3):213-29. PubMed ID: 1726936
[TBL] [Abstract][Full Text] [Related]
10. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
Apasov SG; Sitkovsky MV
J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
[TBL] [Abstract][Full Text] [Related]
11. HLA-restricted recognition of viral antigens in HLA transgenic mice.
Kievits F; Ivanyi P; Krimpenfort P; Berns A; Ploegh HL
Nature; 1987 Oct 1-7; 329(6138):447-9. PubMed ID: 2821399
[TBL] [Abstract][Full Text] [Related]
12. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
Rock KL; Fleischacker C; Gamble S
J Immunol; 1993 Feb; 150(4):1244-52. PubMed ID: 8381832
[TBL] [Abstract][Full Text] [Related]
13. Allospecific cytotoxic T cells generated from beta 2m-/- mice in primary MLC: analysis of activation requirements, specificity, and phenotype.
Lamousé-Smith E; McCarthy SA
Cell Immunol; 1997 Aug; 179(2):107-15. PubMed ID: 9268494
[TBL] [Abstract][Full Text] [Related]
14. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
[TBL] [Abstract][Full Text] [Related]
15. Induction of peptide-specific CD8+ CTL clones in beta 2-microglobulin-deficient mice.
Cook JR; Solheim JC; Connolly JM; Hansen TH
J Immunol; 1995 Jan; 154(1):47-57. PubMed ID: 7995959
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism at position nine of the MHC class I heavy chain affects the stability of association with beta 2-microglobulin and presentation of a viral peptide.
Ribaudo RK; Margulies DH
J Immunol; 1995 Oct; 155(7):3481-93. PubMed ID: 7561043
[TBL] [Abstract][Full Text] [Related]
17. Recognition of the beta-2 microglobulin-B molecule by a CTL clone.
Kurtz ME; Martin-Morgan D; Graff RJ
J Immunol; 1987 Jan; 138(1):87-90. PubMed ID: 3537130
[TBL] [Abstract][Full Text] [Related]
18. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
19. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
20. The association between murine beta 2-microglobulin and HLA class I heavy chains results in serologically detectable conformational changes of both chains.
Ferrier P; Layet C; Caillol DH; Jordan BR; Lemonnier FA
J Immunol; 1985 Aug; 135(2):1281-7. PubMed ID: 2409144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
